Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, Chinot OL (2020) Bevacizumab (Avastin®) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev 86:102017. https://doi.org/10.1016/j.ctrv.2020.102017

Article  CAS  PubMed  Google Scholar 

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342. https://doi.org/10.1056/NEJMoa032691

Article  CAS  PubMed  Google Scholar 

Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550. https://doi.org/10.1056/NEJMoa061884

Article  CAS  PubMed  Google Scholar 

Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MKB, Perren TJ, ICON Group (2015) Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol 16:928–936. https://doi.org/10.1016/S1470-2045(15)00086-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Casak SJ, Donoghue M, Fashoyin-Aje L, Jiang X, Rodriguez L, Shen YL, Xu Y, Jiang X, Liu J, Zhao H, Pierce WF, Mehta S, Goldberg KB, Theoret MR, Kluetz PG, Pazdur R, Lemery SJ (2021) FDA approval summary: atezolizumab plus bevacizumab for the treatment of patients with advanced unresectable or metastatic hepatocellular carcinoma. Clin Cancer Res 27:1836–1841. https://doi.org/10.1158/1078-0432.CCR-20-3407

Article  CAS  PubMed  Google Scholar 

Caulet M, Lecomte T, Bouché O, Rollin J, Gouilleux-Gruart V, Azzopardi N, Léger J, Borg C, Douillard JY, Manfredi S, Smith D, Capitain O, Ferru A, Moussata D, Terrebone E, Paintaud G, Ternant D (2016) Bevacizumab pharmacokinetics influence overall and progression-free survival in metastatic colorectal cancer patients. Clin Pharmacokinet 55:1381–1394. https://doi.org/10.1007/s40262-016-0406-3

Article  CAS  PubMed  Google Scholar 

Papachristos A, Kemos P, Kalofonos H, Sivolapenko G (2020) Correlation between bevacizumab exposure and survival in patients with metastatic colorectal cancer. Oncologist 25:853–858. https://doi.org/10.1634/theoncologist.2019-0835

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gill KL, Machavaram KK, Rose RH, Chetty M (2016) Potential sources of inter-subject variability in monoclonal antibody pharmacokinetics. Clin Pharmacokinet 55:789–805. https://doi.org/10.1007/s40262-015-0361-4

Article  CAS  PubMed  Google Scholar 

Joy MS, Gipson DS, Powell L, MacHardy J, Jennette JC, Vento S, Pan C, Savin V, Eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H (2010) Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. Am J Kidney Dis 55:50–60. https://doi.org/10.1053/j.ajkd.2009.08.019

Article  CAS  PubMed  Google Scholar 

Fogueri U, Cheungapasitporn W, Bourne D, Fervenza FC, Joy MS (2019) Rituximab exhibits altered pharmacokinetics in patients with membranous nephropathy. Ann Pharmacother 53:357–363. https://doi.org/10.1177/1060028018803587

Article  CAS  PubMed  Google Scholar 

Masuda T, Funakoshi T, Horimatsu T, Yamamoto S, Matsubara T, Masui S, Nakagawa S, Ikemi Y, Yanagita M, Muto M, Terada T, Yonezawa A (2024) Low serum concentrations of bevacizumab and nivolumab owing to excessive urinary loss in patients with proteinuria: a case series. Cancer Chemother Pharmacol 94:615–622. https://doi.org/10.1007/s00280-024-04659-3

Article  PubMed  Google Scholar 

Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J (2008) Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 62:779–786. https://doi.org/10.1007/s00280-007-0664-8

Article  CAS  PubMed  Google Scholar 

Li J, Gupta M, Jin D, Xin Y, Visich J, Allison DE (2013) Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon. Cancer Chemother Pharmacol 71:575–580. https://doi.org/10.1007/s00280-012-2031-7

Article  CAS  PubMed  Google Scholar 

Panoilia E, Schindler E, Samantas E, Aravantinos G, Kalofonos HP, Christodoulou C, Patrinos GP, Friberg LE, Sivolapenko G (2015) A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients. Cancer Chemother Pharmacol 75:791–803. https://doi.org/10.1007/s00280-015-2701-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li CSW, Sweeney K, Cronenberger C (2020) Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin®) in patients with advanced non-squamous non-small cell lung cancer. Cancer Chemother Pharmacol 85:487–499. https://doi.org/10.1007/s00280-019-03946-8

Article  CAS  PubMed  Google Scholar 

Petitcollin A, Azzopardi N, Pierga JY, Ternant D, Navarro-Teulon I, Desvignes C, Mouret-Reynier MA, Coudert B, Paintaud G (2021) Population pharmacokinetics and exposure-response relationship of trastuzumab and bevacizumab in early-stage breast cancer. Eur J Clin Pharmacol 77:1861–1873. https://doi.org/10.1007/s00228-021-03179-w

Article  CAS  PubMed  Google Scholar 

Beal SL (2001) Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28:481–504. https://doi.org/10.1023/a:1012299115260

Article  CAS  PubMed  Google Scholar 

Iwamoto N, Shimada T, Umino Y, Aoki C, Aoki Y, Sato TA, Hamada A, Nakagama H (2014) Selective detection of complementarity-determining regions of monoclonal antibody by limiting protease access to the substrate: nano-surface and molecular-orientation limited proteolysis. Analyst 139:576–580. https://doi.org/10.1039/c3an02104a

Article  CAS  PubMed  Google Scholar 

Iwamoto N, Umino Y, Aoki C, Yamane N, Hamada A, Shimada T (2016) Fully validated LCMS bioanalysis of bevacizumab in human plasma using nano-surface and molecular-orientation limited (nSMOL) proteolysis. Drug Metab Pharmacokinet 31:46–50. https://doi.org/10.1016/j.dmpk.2015.11.004

Article  CAS  PubMed  Google Scholar 

Roberts BV, Susano I, Gipson DS, Trachtman H, Joy MS (2013) Contribution of renal and non-renal clearance on increased total clearance of adalimumab in glomerular disease. J Clin Pharmacol 53:919–924. https://doi.org/10.1002/jcph.121

Article  CAS  PubMed  Google Scholar 

Ng CM, Lum BL, Gimenez V, Kelsey S, Allison D (2006) Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res 23:1275–1284. https://doi.org/10.1007/s11095-006-0205-x

Article  CAS  PubMed  Google Scholar 

Fasanmade AA, Adedokun OJ, Ford J, Hernandez D, Johanns J, Hu C, Davis HM, Zhou H (2009) Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol 65:1211–1228. https://doi.org/10.1007/s00228-009-0718-4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu Y, Hu C, Lu M, Liao S, Marini JC, Yohrling J, Yeilding N, Davis HM, Zhou H (2009) Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 49:162–175. https://doi.org/10.1177/0091270008329556

Article  CAS  PubMed  Google Scholar 

Kim J, Hayton WL, Robinson JM, Anderson CL (2007) Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model. Clin Immunol 122:146–155. https://doi.org/10.1016/j.clim.2006.09.001

Article  CAS  PubMed  Google Scholar 

Chaudhury C, Mehnaz S, Robinson JM, Hayton WL, Pearl DK, Roopenian DC, Anderson CL (2003) The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan. J Exp Med 197:315–322. https://doi.org/10.1084/jem.20021829

Article  CAS  PubMed  PubMed Central